Abivax has presented new preclinical and clinical data for obefazimod [...]

Long-term VIVID-2 data show more than 90% of patients with [...]

Amorphical has announced positive final long-term results from its Phase [...]

The Scottish Medicines Consortium (SMC) has accepted guselkumab for the [...]

Immunai has signed an agreement worth up to $85 million [...]

Amorphical, developer of nano-amorphous mineral-based pharmacologic agents, has announced positive [...]

Enhanced Genomics has secured an additional funding round, bringing its [...]

MRM Health, a clinical stage biopharmaceutical company developing microbiome-based therapeutics, [...]

Mirikizumab is now recommended by NICE for routine NHS use [...]

UK-based biotech N4 Pharma has announced encouraging in vivo results [...]